![]() | |
Clinical data | |
---|---|
Trade names | Iomervu, others |
License data | |
Routes of administration | Intravenous, intra-arterial |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | none |
Elimination half-life | 109±20 min |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H22I3N3O8 |
Molar mass | 777.089 g·mol−1 |
3D model (JSmol) | |
| |
|
Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging. [1] [2] [3]
Iomeprol was approved for medical use in the United States in November 2024. [1] [4] [5]
It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium. [2] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents. [2]
Iomeprol is not metabolized in the human body but excreted in unchanged form.[ medical citation needed ] It is decomposed slowly and can therefore accumulate in the environment. [6]
Iomeprol was approved for medical use in the United States in November 2024. [1] [4]
Iomeprol is sold under the brand name Iomervu. [1]